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TO THE EDITOR 
 
Pathologies associated with genodermatoses and other genetic disorders can irremediably 
affect fetuses, making early stage therapies desirable. Prenatal maternal drug administration, 
however, exposes mothers to potential drug toxicity and is limited by the variability in 
transplacental drug delivery. Alternative approaches to fetal treatment should entail low risk 
drug delivery with reproducible pharmacokinetics. X-linked hypohidrotic ectodermal 
dysplasia (XLHED), the most common inherited disorder of ectoderm development, is caused 
by a lack of the signaling molecule ectodysplasin A1 (EDA1) which is essential for 
ectodermal placode formation and subsequent development of various skin appendages, 
glands, and teeth (Mikkola, 2009). Patients with XLHED have less hair, fewer or no eccrine 
sweat, sebaceous and meibomian glands, and malformed or absent teeth. Insufficient 
thermoregulation can lead to perilous hyperthermic episodes during infancy (Blüschke et al, 
2010) and remains an important issue throughout life (Hammersen et al, 2011). Many affected 
individuals suffer from recurrent airway and eye problems (Dietz et al, 2013). To date only 
symptomatic treatment is available for these patients.  
Causative therapeutic approaches are expected to be most effective if applied already in utero, 
with the additional benefit that immune tolerance of a replacement protein may be induced, 
facilitating postnatal re-application (Schneider et al, 2002; Waddington et al, 2003). In the 
Tabby mouse, a well-characterized animal model of XLHED (Falconer, 1952), prenatal 
exposure to EDA1 via serial intravenous administrations to the dam corrected developmental 
abnormalities to a far greater extent than postnatal administration (Gaide and Schneider, 
2003). This approach may, however, be suboptimal for achieving reproducible therapeutic 
drug concentrations in human fetuses, and would expose the mother to high serum levels of 
an exogenous molecule. We hypothesized that EDI200, an EDA1 replacement protein 
consisting of the receptor-binding domain of EDA1 and the Fc part of IgG1, may enter the 
fetal circulation also after injection into the amniotic fluid (AF), because the fetus swallows 
AF regularly and the neonatal Fc receptor which is present in rodent and human fetal intestine 
(Shah et al, 2003) may facilitate intestinal absorption of Fc-containing proteins. AF could thus 
serve as a drug reservoir and provide for continuous drug uptake. Here we report striking 
reversal of the XLHED phenotype of Tabby mice following a single intra-amniotic injection 
of EDI200. 
Long-term stability of this recombinant protein in AF, i.e. the retention of binding to its 
cognate receptor, was confirmed in vitro under various conditions (Figure S1). 
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Pharmacokinetics following intra-amniotic injection of 35 µg EDI200 per amniotic sac (= 100 
µg/g of estimated fetal body weight) was studied in wild-type mice at day 15 of gestation 
(E15). EDI200 serum levels were measured at different time points after injection both in 
treated and untreated fetuses as well as in the dams. All maternal animals recovered well from 
the intervention; 93% of the treated fetuses survived. Intra-amniotic injection of EDI200 
resulted in mean fetal serum levels of 9.0 µg/ml and 1.2 µg/ml at 6 and 96 hours, respectively. 
After 6 hours, this corresponds to 180 ng of EDI200 per fetus, or 0.5% of the injected protein, 
assuming a total serum volume of approximately 20 µl in an E15 mouse fetus. Interestingly, 
there was a low level of EDI200 transfer into the circulation of untreated siblings and that of 
the pregnant dam (Figure 1). The drug was partially and slowly redistributed from treated 
fetuses, in which EDI200 concentration diminished over time, to untreated siblings that 
witnessed a parallel increase of the serum levels (up to 0.57 µg/ml). Maternal EDI200 serum 
levels remained <0.1 µg/ml at the time points investigated. Thus, intra-amniotic 
administration of EDI200 at E15 resulted in substantial fetal uptake with minimal maternal 
exposure.  
This approach was then evaluated in pregnant Tabby mice with doses of 100, 10, and 1 µg/g 
of estimated fetal body weight. All treated Tabby mouse fetuses of the high and intermediate 
dose cohorts survived the E15 intra-amniotic injection and were born without complications. 
They were easily distinguishable from native Tabby mice already in the second week after 
birth. Later, normal eye opening, retro-auricular and guard hair as in wild-type mice, and a 
normally shaped tail tip (Figure 2 a, b) were evident. Starch-iodine tests revealed regular 
sweat production at the paws (Figure 2 c-e). Normal eccrine sweat glands (Figure 2 f-h) were 
detected in footpads of these animals. In addition, size and shape of the molars resembled 
those of wild-type mice (Figure 2 i-k).  
Thus, in contrast to a single maternal intravenous injection of 400 µg of EDI200 in pregnant 
Tabby mice at E15, which corrected the XLHED phenotype in the offspring only partially 
(unpublished own data), a single intra-amniotic dose of 3.5 µg or above resulted in complete 
phenotypic correction. No adverse effects were observed. All treated Tabby mice survived to 
adulthood and showed normal behavior and fertility. The lower dose of 1 µg/g body weight 
yielded only a partial restoration of normal ectoderm development, with less guard and/or tail 
hair and fewer sweat glands present (Table S1). Interestingly, but less relevant to human 
singleton gestations, a dose-dependent correction was also observed for untreated littermates 
(Table S1) – explained by partial leakage of the drug to neighboring fetuses. As expected 
from previous studies (Gaide and Schneider, 2003), the maternal Tabby phenotype was not 
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visibly altered by EDI200 administration, regardless of the dose. All dams remained fertile 
and no adverse effects of the treatment could be detected during an observation period of 6 to 
9 months.  
 
The EDA1 signaling pathway is well conserved among vertebrates (Pantalacci et al, 2008) 
and findings in animal models should therefore be transferable to human XLHED patients. 
Early corrective treatment would increase their life expectancy, would have a high impact on 
the quality of life and substantially reduce medical expenses. Intra-amniotic drug delivery 
might be most beneficial if attempted during mid-gestation, when sweat gland development is 
not yet completed (Ersch and Stallmach, 1999). This approach is likely to have a good 
benefit/risk ratio, supported by the broad experience with amniocentesis, and may represent a 
novel paradigm for treatment of disorders in early human development.  
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FIGURE LEGENDS 
 
Figure 1: EDI200 pharmacokinetics after intra-amniotic administration to mice 
EDI200 was injected into amniotic sacs of 4 pregnant wild-type mice carrying a total of 23 
fetuses at day E15 (100 µg/g of estimated fetal body weight). Some fetuses of each mother 
were left untreated. Another pregnant mouse and the fetuses of her served as negative 
controls. EDI200 serum concentrations were measured at different time points by receptor-
binding ELISA. Highest serum levels were detected 6 hours after the injection. There was 
some leakage to untreated siblings and, to a lower extent, into the mother’s circulation. n.a., 
not applicable; * p<0.05; ** p<0.01.  
   
Figure 2: Phenotype after prenatal treatment with EDI200 
Tabby mice were treated in utero (E15) by a single intra-amniotic injection of EDI200 (here 
100 µg/g) and investigated postnatally. Age-matched native Tabby mice (a) could be 
distinguished clearly from treated animals (b), which had a darker and denser coat, showed 
normal eye opening and hair around the eye, retro-auricular and guard hair like wild-type 
mice, and a hairy, normally shaped tail. Starch-iodine tests of the paws revealed numerous 
dark spots in a characteristic pattern indicating functional sweat glands (c). Histological 
analysis of footpad sections confirmed the presence of fully developed eccrine sweat glands in 
the treated animals (f). Native Tabby mice (d, g) and wild-type mice (e, h) served as controls. 
Molars of treated Tabby mice (i) were altogether larger than those of native Tabby mice (j) 
and showed similar shape and cusps pattern as in wild-type animals (k).  
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Supplementary	  information	  	  
	  
MATERIALS	  AND	  METHODS	  
Reagents	  and	  human	  samples	  
EDI200,	  a	  recombinant	  fusion	  protein	  consisting	  of	  the	  receptor-­‐binding	  domain	  of	  EDA1	  (aa	  
238-­‐391)	  and	  the	  Fc	  part	  of	  IgG1,	  was	  provided	  by	  Edimer	  Pharmaceuticals,	  Inc.	  (Cambridge,	  
USA).	  The	  antibodies	  mAbEDAR1,	  an	  anti-­‐EDAR	  mouse	  IgG1	  antibody	  (Kowalczyk	  et	  al,	  2011),	  
EctoD2	   and	   biotinylated	   EctoD3,	   two	   murine	   antibodies	   recognizing	   EDA1	   (Kowalczyk-­‐
Quintas	  et	  al,	  2014),	  and	  hEDAR-­‐hFc	   (Kowalczyk	  et	  al,	  2011)	  were	  described	  previously.	  To	  
produce	  hEDAR-­‐mFc,	  an	  appropriate	  expression	  plasmid	  [hEDAR	  (aa	  1-­‐183)-­‐mIgG1	  (aa	  235-­‐
461	  of	  GenBank	  accession	  number	  AAA75163.1)]	  was	   generated	  and	   introduced	   into	  CHO	  
cells	  (Sigma),	  yielding	  a	  stable	  hEDAR-­‐mFc-­‐secreting	  cell	  clone.	  The	  protein	  was	  purified	  from	  
conditioned	   supernatants	   by	   affinity	   purification	   on	   immobilized	   mAbEDAR1,	   which	   was	  
coupled	  to	  NHS-­‐activated	  Sepharose	  (GE	  Healthcare)	  at	  a	  ratio	  of	  5	  mg	  antibody	  per	  ml	  of	  
Sepharose	  according	  to	  the	  manufacturer’s	  instructions.	  Fresh	  human	  amniotic	  fluid	  (pooled	  
remnants	   from	   two	  elective	  amniocentesis	   samples)	  was	  obtained	  with	   informed	  consent,	  
kept	  at	  4°C	  and	  used	  within	  24	  hours.	  	  
	  
Incubations	  in	  amniotic	  fluid	  
Protein	  stability	  in	  AF	  was	  evaluated	  essentially	  as	  described	  previously	  (Schmidt	  et	  al,	  2004).	  
EDI200	   was	   incubated	   in	   fresh	   human	   AF,	   from	   which	   cellular	   components	   had	   been	  
removed	   or	   not	   by	   centrifugation,	   at	   concentrations	   of	   10	   or	   500	   µg/ml	   at	   37°C	   in	   the	  
presence	   of	   penicillin	   (50	   U/ml)	   and	   streptomycin	   (50	   µg/ml).	   Aliquots	   were	   removed	   at	  
different	  time	  points	  (0,	  0.5,	  4,	  24,	  72,	  and	  168	  h)	  and	  immediately	  stored	  at	  -­‐80°C	  until	  use.	  
A	  comparable	  series	  of	  samples	  was	  obtained	  after	  exposure	  of	  EDI200	  to	  fresh	  human	  AF	  at	  
4°C.	  All	  samples	  were	  then	  investigated	  in	  parallel	  by	  receptor-­‐binding	  ELISA.	  	  
	  
Receptor-­‐binding	  ELISA	  
For	  the	  detection	  of	  EDI200,	  ELISA	  plates	  (Nunc	  Maxisorb)	  were	  coated	  with	  hEDAR-­‐mFc	  (0.2	  
µg/ml	  PBS)	  and	  blocked	  with	  a	  solution	  of	  skimmed	  milk	  powder	  (4%)	  and	  Tween-­‐20	  (0.5	  %)	  
in	  PBS.	  Serial	  dilutions	  of	  EDI200	  samples	  prepared	  in	  a	  separate,	  pre-­‐saturated	  plate	  were	  
added,	  and	  binding	  was	  revealed	  with	  horseradish	  peroxidase-­‐coupled	  goat	  anti-­‐human-­‐IgG	  
2 
 
(JIR	  109-­‐005-­‐033),	  followed	  by	  addition	  o-­‐phenylenediamine	  substrate	  (Sigma).	  The	  reaction	  
was	  stopped	  with	  acid	  and	  absorbance	  was	  read	  at	  492	  nm.	  Binding	  of	  mAbEDAR1	  to	  EDAR	  
was	  evaluated	  in	  plates	  coated	  with	  hEDAR-­‐hFc	  (0.2	  µg/ml	  PBS).	  After	  blocking	  of	  the	  plate,	  
serial	   dilutions	   of	  mAbEDAR1	  were	   added	   and	   the	   binding	  was	   revealed	  with	   horseradish	  
peroxidase-­‐coupled	  goat	  anti-­‐mouse	  IgG	  (JIR	  115-­‐036-­‐166).	  For	  the	  quantification	  of	  EDI200	  
by	  sandwich	  ELISA	  (Kowalczyk-­‐Quintas	  et	  al,	  2014),	  ELISA	  plates	  were	  coated	  with	  EctoD2	  (5	  
µg/ml	  of	  PBS)	  and	  blocked.	  Twenty-­‐fold	  diluted	  serum	  samples	  (100	  µl)	  were	  added	  to	  each	  
well,	   and	   captured	   EDI200	   was	   revealed	   with	   biotinylated	   EctoD3	   (1	   µg/ml)	   followed	   by	  
peroxidase-­‐coupled	   streptavidin.	   Concentrations	  of	   EDI200	  were	   calculated	  by	   comparison	  
with	  a	  standard	  curve	  of	  EDI200	  in	  PBS.	  The	  lower	  limit	  of	  quantitation	  (LLQ)	  was	  0.8	  ng/ml.	  
	  
Animals	  and	  surgical	  procedures	  
C57BL/6	   wild-­‐type	   mice	   (Charles	   River)	   and	   white-­‐bellied	   agouti	   B6CBAa	   Aw-­‐J/A-­‐EdaTa/J	  
Tabby	  mice	  (000314;	  Jackson	  Laboratory)	  were	  housed	  in	  individually	  ventilated	  cages	  under	  
standard	  conditions	  with	  a	  light/dark	  cycle	  of	  12	  hours	  and	  free	  access	  to	  standard	  chow	  and	  
tap	   water.	   All	   experimental	   procedures	   were	   conducted	   in	   accordance	   with	   the	   German	  
regulations	  and	  legal	  requirements.	  	  
Blood	   samples	   from	   adult	   animals	   were	   obtained	   by	   puncture	   of	   the	   retrobulbar	   venous	  
plexus	   and	   post-­‐coagulation	   serum	   was	   stored	   at	   -­‐20°C.	   Intra-­‐amniotic	   injections	   were	  
performed	  essentially	   as	   follows:	   Timed-­‐mated	  pregnant	  mice	  on	  gestational	   day	  15	   (E15)	  
were	  anesthetized	  with	  isofluran	  (2%).	  For	  perioperative	  analgesia,	  metamizole	  (100	  µl)	  was	  
administered	  subcutaneously.	  The	  abdominal	  cavity	  was	  opened	  by	  midline	  laparotomy	  and	  
both	  uterine	  horns	  were	  exposed	  completely.	  EDI200	  was	  injected	  into	  the	  amniotic	  sacs	  of	  
individual	  fetuses	  at	  doses	  between	  1	  and	  100	  µg/g	  of	  fetal	  body	  weight	  (16	  µl	  of	  EDI200	  at	  
2.2	  mg/ml,	  assuming	  a	  maximum	  fetal	  weight	  of	  0.35	  g)	  using	  glass	  syringes	  with	  33	  gauge	  
needles	  (Hamilton).	  The	  amniotic	  sacs	  of	  some	  fetuses	  were	  left	  untreated.	  The	  uterus	  was	  
then	  placed	  back	  in	  the	  abdomen,	  and	  the	  abdominal	  wall	  was	  closed	  by	  continuous	  suture	  
of	  the	  peritoneal	  layer	  and	  interrupted	  stitches	  of	  the	  skin.	  All	  mice	  were	  allowed	  to	  recover	  
in	  a	  pre-­‐warmed	  cage.	  Wild-­‐type	  mice	  were	  sacrificed	  6,	  24	  or	  96	  h	  after	  the	   intervention.	  
Fetuses	  were	  delivered	  by	  Cesarian	  section.	  Each	  amniotic	  sac	  was	  dissected	  individually	  and	  
the	   fetus	   was	   washed	   several	   times	   in	   saline	   prior	   to	   decapitation	   to	   obtain	   fetal	   blood.	  
Treated	  fetuses	  were	  distinguishable	  from	  untreated	  fetuses	  by	  their	  position	  in	  the	  uterus.	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Maternal	  blood	  was	  collected	  by	  cardiac	  puncture.	  Post-­‐coagulation	  serum	  was	  stored	  at	   -­‐
20°C.	  Tabby	  mice	  were	  allowed	  to	  deliver	  normally	  and	  were	  left	  with	  their	  pups.	  	  
	  
Phenotypic	  characterization	  
The	   offspring	   of	   Tabby	   mice	   was	   investigated	   at	   the	   time	   points	   indicated	   for	   various	  
morphological	  features	  (tail	  hair,	  shape	  of	  the	  tail	  tip,	  guard	  hair,	  eyes,	  etc.).	  Treated	  animals	  
were	  distinguished	  from	  untreated	  littermates	  by	  their	  phenotypic	  reversion,	  assuming	  that	  
treated	   pups	   would	   be	   reverted	   to	   a	   greater	   extent	   than	   untreated	   ones.	   Starch/iodine	  
sweat	  tests	  were	  performed	  as	  described	  previously	  (Gaide	  and	  Schneider,	  2003).	  Briefly,	  the	  
palmar	  side	  of	  a	  hind	  paw	  of	  the	  immobilized	  mouse	  was	  covered	  with	  a	  solution	  of	  3%	  (w/v)	  
iodine	   in	   ethanol	   and	  allowed	   to	  dry	   at	   the	   air.	   Then	  a	   suspension	  of	   40%	   (w/v)	   starch	   in	  
mineral	  oil	  was	  applied.	  Pictures	  were	  taken	  after	  one	  minute;	  sweat	  pores	  appeared	  as	  dark	  
spots.	  
	  
Histological	  analyses	  
Tissue	  samples	  from	  skin,	  eyelids,	  footpads	  and	  tail	  were	  fixed	  in	  4%	  paraformaldehyde	  for	  
24	   hours.	   After	   dehydration	   and	   paraffin	   embedding,	   sections	   were	   cut	   and	   stained	  with	  
hematoxylin	  and	  eosin	   for	  morphological	  evaluation.	   Jaws	  of	  adult	  mice	  were	  boiled	   for	  2	  
hours	  in	  water	  containing	  10	  g	  of	  a	  standard	  dishwasher	  tab	  per	  100	  ml,	  cleansed	  manually	  
of	  adherent	  tissue	  and	  bleached	  with	  30%	  hydrogen	  peroxide.	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Figure	  S1:	  	  Stability	  of	  EDI200	  in	  amniotic	  fluid	  	  
EDI200	   and	   an	   anti-­‐EDAR	   antibody	   (mAbEDAR1)	   were	   incubated	   with	   fresh	   human	   AF	   at	  
37°C	   or	   left	   standing	   at	   4°C.	   Aliquots	   taken	   at	   the	   time	   points	   indicated	   were	   tested	   by	  
receptor-­‐binding	   ELISA.	   A.	   The	   ability	   of	   the	   anti-­‐EDAR	   antibody	   to	   recognize	   hEDAR-­‐hFc	  
remained	  unaffected	  by	  incubation	  in	  AF	  at	  37°C	  for	  up	  to	  7	  days.	  B.	  The	  ability	  of	  EDI200	  to	  
bind	   to	  hEDAR-­‐mFc	  was	  also	  not	  affected	  by	   incubation	   in	  AF.	  C.	   There	  was	  no	   significant	  
alteration	  of	  the	  ability	  of	  EDI200	  (or	  mAbEDAR1)	  to	  bind	  to	  hEDAR-­‐mFc	  after	  exposure	  to	  AF	  
for	  7	  days	  under	  the	  conditions	  indicated.	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SUPPLEMENTARY	  TABLE	  
 
	   Tail	  
hair	  
Tail	  
shape	  
Hair	  behind	  
the	  ears	  
Guard	  
hair	  
Eyes	   Teeth	   Sweat	  
glands	  
Progeny	  
after	  mating	  
EDI200,	  1	  µg/g	  
(group	  A;	  n=5)	  
1.6	   1.8	   2.0	   2.0	   1.0	   1.4	   1.0	   n.a.	  
Untreated	  siblings	  
of	  group	  A	  (n=4)	  
0.25	   0	   0	   0	   0	   0	   0	   n.a.	  
EDI200,	  10	  µg/g	  
(group	  B;	  n=4)	  
3.0	   3.0	   3.0	   3.0	   3.0	   2.75	   2.75	   4/4	  
Untreated	  siblings	  
of	  group	  B	  (n=1)	  
2.0	   2.0	   3.0	   2.0	   2.0	   2.0	   1.0	   1/1	  
EDI200,	  100	  µg/g	  
(group	  C;	  n=7)	  
3.0	   3.0	   3.0	   3.0	   3.0	   3.0*	   3.0	   7/7	  
Untreated	  siblings	  
of	  	  group	  C	  (n=2)	  
3.0	   2.5	   3.0	   3.0	   3.0	   3.0*	   3.0	   2/2	  
	  
3	  =	  fully	  corrected	  
2	  =	  partially	  corrected,	  close	  to	  wild-­‐type	  
1	  =	  partially	  corrected,	  close	  to	  native	  Tabby	  mice	   	  	  	  	  	  	  	  
0	  =	  no	  correction	  
n.a.,	  data	  not	  yet	  available	  
*	  only	  one	  animal	  analyzed;	  the	  others	  were	  kept	  for	  long-­‐term	  follow-­‐up	  
	  
Table	  S1:	  	  Summary	  of	  phenotypic	  findings	  after	  intra-­‐amniotic	  EDI200	  application	  to	  fetal	  
Tabby	  mice	  
EDI200	  injection	  led	  to	  a	  striking,	  dose-­‐dependent	  reversion	  to	  a	  normal	  phenotype.	  A	  dose-­‐
dependent	  correction	  was	  also	  observed	  for	  “untreated”	  siblings.	  	  
 
